Healthcare
Live Price
Offline$1,133.00
-2.41% today
1Y Change
+47.02%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Eli Lilly and Company (LLY) is a Healthcare stock with a market cap of $915.33B and listed on NYSE. The stock last traded around $1133.00 and up 47.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +44.7%, EPS growth of +95.6%, a dividend yield of 0.6%. What stands out right now is revenue +44.7%, EPS +95.6%, free cash flow +2065.6% with operating margin 45.9% and ROIC 32.1%. The dividend is present but secondary, with a yield around 0.6%. Valuation already assumes a fairly strong business story at P/E 34.3 and price/sales 12.7. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines LLY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
LLY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
LLY Max Drawdown
-23.31%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for LLY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$28.3B
-0.8% YoY
FY Net Income
$5.6B
-10.6% YoY
Free Cash Flow
$5.4B
+17.1% YoY
Revenue Growth
+44.7%
EPS Growth
+95.6%
Gross Margin
83.5%
Net Margin
35.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 65.2B | 45.0B | 34.1B | 28.5B | 28.3B |
| Gross Profit | 54.6B | 36.6B | 27.0B | 21.9B | 21.0B |
| Operating Income | 29.7B | 17.5B | 10.8B | 8.7B | 7.9B |
| EBITDA | 27.9B | 15.2B | 8.6B | 8.7B | 8.0B |
| Net Income | 20.6B | 10.6B | 5.2B | 6.2B | 5.6B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 7.2B | 3.3B | 2.8B | 2.1B | 3.8B |
| Total Assets | 112.5B | 78.7B | 64.0B | 49.5B | 48.8B |
| Total Liabilities | 85.9B | 64.4B | 53.1B | 38.7B | 39.7B |
| Shareholder Equity | 26.5B | 14.2B | 10.8B | 10.6B | 9.0B |
| Total Debt | 42.5B | 33.6B | 25.2B | 16.2B | 16.9B |
| Net Debt | 35.3B | 30.4B | 22.4B | 14.2B | 13.1B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
7.4B
-2.9% YoY
Capital Expenditures
2.0B
+33.7% YoY
Free Cash Flow
5.4B
+17.1% YoY
Key ratios
Gross Margin
83.5%
Operating Margin
45.9%
Net Margin
35.0%
ROE
101.3%
Debt / Equity
1.39x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.